

## Assoc. Prof. NAIL PAKSOY

### Personal Information

**Email:** nail.paksoy@medipol.edu.tr

**Web:** <https://avesis.medipol.edu.tr/nail.paksoy>

### International Researcher IDs

ScholarID: fdkYW4kAAAAJ

ORCID: 0000-0003-4636-2595

Publons / Web Of Science ResearcherID: HKF-3015-2023

ScopusID: 57205608177

Yoksis Researcher ID: 165583

### Education Information

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 2018 - 2021

Expertise In Medicine, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, Turkey 2012 - 2017

Undergraduate, Turkey 2005 - 2011

### Foreign Languages

German, B1 Intermediate

English, B1 Intermediate

### Certificates, Courses and Trainings

Vocational Training, ESMO Board Certification in Medical Oncology, European Society for Medical Oncology (ESMO), 2022

### Research Areas

Health Sciences

### Academic Titles / Tasks

Associate Professor, Istanbul Medipol University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2024 - Continues

Research Assistant, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , 2018 - 2022

Research Assistant, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , 2017 - 2018

Research Assistant, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, 2012 - 2017

- I. **Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases**  
Kahraman S., Karakaya S., Kaplan M. A., Goksu S. S., Ozturk A., Isleyen Z. S., Hamdard J., Yildirim S., Dogan T., Isik S., et al.  
Scientific Reports, vol.14, no.1, 2024 (SCI-Expanded)
- II. **Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer**  
Taşçı E. Ş., Oyan B., Sönmez Ö., Mutlu A. U., Atıcı M. M., Sakin A., Öner İ., Çınkır H. Y., Eryılmaz M. K., Çağlayan D., et al.  
BMC Cancer, vol.24, no.1, 2024 (SCI-Expanded)
- III. **Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy**  
Meagher M. F., Minervini A., Mir M. C., Cerrato C., Rebez G., Autorino R., Hampton L., Campi R., Kriegmair M., Linares E., et al.  
European Urology Open Science, vol.63, pp.71-80, 2024 (SCI-Expanded)
- IV. **Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study**  
DEMİRCİ N. S., AZİZY A., Paksoy N., Doğan I., KARABULUT S., Karahan L., TAŞTEKİN D.  
Medicine (United States), vol.103, no.9, 2024 (SCI-Expanded)
- V. **Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study**  
Ferhatoglu F., Paksoy N., Khanmammadov N., YILDIZ A., AHMED M. A., Gülbas Z., BAŞARAN M.  
Medicine (United States), vol.103, no.8, 2024 (SCI-Expanded)
- VI. **Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients**  
Dogan I., Paksoy N., BAŞARAN M.  
Journal of Cancer Research and Therapeutics, vol.20, no.1, pp.93-97, 2024 (SCI-Expanded)
- VII. **The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients**  
Ak N., Tuz Z., Aydin E., Ferhatoglu F., Sari M., Paksoy N., Doğan I., Yildiz A., Dişçi R., Saip P. M.  
Turkish Journal of Medical Sciences, vol.54, no.1, pp.229-238, 2024 (SCI-Expanded)
- VIII. **Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression**  
Dogan I., Aydin E., Khanmammadov N., Paksoy N., Saip P., AYDINER A.  
Scientific Reports, vol.13, no.1, 2023 (SCI-Expanded)
- IX. **Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy**  
Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., Selvi O., Erdem D., Avşar E., Paksoy N., et al.  
BMC Cancer, vol.23, no.1, 2023 (SCI-Expanded)
- X. **Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients**  
Dogan I., Aydin E., Khanmammadov N., Paksoy N., Ferhatoglu F., Ak N., Emiroglu S., İBİŞ K., Onder S., Tukenmez M., et al.  
Journal of Cancer Research and Clinical Oncology, vol.149, no.16, pp.14833-14841, 2023 (SCI-Expanded)
- XI. **Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience**  
Pehlivan M., Paksoy N., Aydin E., BAŞARAN M., EKENEL M.  
Medicine (United States), vol.102, no.41, 2023 (SCI-Expanded)
- XII. **Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group**  
Ünal Ç., Azizy A., Karabulut S., Taştekin D., Akyıldız A., Yaşar S., Yalçın Ş., Çoban E., Evrensel T., Kalkan Z., et al.

Oncologist, vol.28, no.10, pp.875-884, 2023 (SCI-Expanded)

- XIII. **Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center**  
Khanmammadov N., Paksoy N., Dogan I., Ferhatoglu F., Saip P., AYDINER A.  
Medicine (United States), vol.102, no.39, 2023 (SCI-Expanded)
- XIV. **The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)**  
Hizal M., Bilgin B., Paksoy N., Atci M. M., Kahraman S., Kılıçkap S., Güven D. C., Keskinliç M., Ayhan M., Eren Ö., et al.  
Journal of Cancer Research and Clinical Oncology, vol.149, no.8, pp.4141-4148, 2023 (SCI-Expanded)
- XV. **Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases**  
Dogan I., Iribas A., Paksoy N., Vatansever S., BAŞARAN M.  
Journal of Cancer Research and Therapeutics, vol.19, no.2 S, 2023 (SCI-Expanded)
- XVI. **Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer**  
Kahraman S., Erul E., Seyyar M., Gumusay O., Bayram E., Demirel B. C., Acar O., Aksoy S., Baytemur N. K., Sahin E., et al.  
Future Oncology, vol.19, no.10, pp.727-736, 2023 (SCI-Expanded)
- XVII. **Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience**  
TAŞTEKİN D., Paksoy N., Dogan I., Ferhatoglu F., Khanmammadov N., Bozbey H. U., KARABULUT S.  
Journal of Cancer Research and Therapeutics, vol.19, no.2, pp.253-258, 2023 (SCI-Expanded)
- XVIII. **Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group**  
Gürbüz M., Kiliçkap S., BİLİCİ A., Karadurmuş N., Sezer A., ŞENDUR M. A. N., PAYDAŞ S., Artaç M., Fulden Yumuk P., Gürsoy P., et al.  
Medicine (United States), vol.101, no.50, 2022 (SCI-Expanded)
- XIX. **High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience**  
Paksoy N., Ferhatoglu F., Dogan İ., Khanmammadov N., Iribas Celik A., Gulbas Z., BAŞARAN M.  
Medicine (United States), vol.101, no.49, 2022 (SCI-Expanded)
- XX. **Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group**  
Gürbüz M., KUTLU Y., Akkuş E., KÖKSOY E. B., Köse N., Öven B. B., Uluç B. O., Demiray A. G., Erdem D., Demir B., et al.  
Journal of Cancer Research and Clinical Oncology, vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded)
- XXI. **Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study**  
Paksoy N., Khanmammadov N., Doğan İ., Ferhatoğlu F., YILDIZ A., Ak N., AYDINER A.  
Medicine (United States), vol.101, no.45, 2022 (SCI-Expanded)
- XXII. **Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC**  
Dogan I., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., DEMİRKAZIK A., AYDINER A.  
Medicine (United States), vol.101, no.34, 2022 (SCI-Expanded)
- XXIII. **Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer**  
Dogan I., KARABULUT S., TAŞTEKİN D., Ferhatoglu F., Paksoy N., ŞAKAR B.  
Journal of the College of Physicians and Surgeons Pakistan, vol.32, no.8, pp.1014-1019, 2022 (SCI-Expanded)
- XXIV. **Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study**  
Hizal M., Bilgin B., Paksoy N., Kılıçkap S., Atci M. M., Kahraman S., Keskinliç M., Bilgetekin A., Ayhan M., Tural D., et al.  
Future Oncology, vol.18, no.23, pp.2573-2582, 2022 (SCI-Expanded)

- XXV. **The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study**  
Hizal M, Bilgin B, Paksoy N, AÇIKGÖZ Ö, Sezer A, Gürbüz M, Ak N, Yücel Ş, Ayhan M, Erol C, et al.  
Journal of Cancer Research and Clinical Oncology, vol.148, no.6, pp.1501-1508, 2022 (SCI-Expanded)
- XXVI. **Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study**  
Cil I, Kucukarda A, Atci M. M., Secmeler S, Paksoy N, Ferhatoglu F, Ak N, Ayhan M, Tataroglu Ozyukseler D, Onder A. H., et al.  
Tumori, vol.108, no.1, pp.19-25, 2022 (SCI-Expanded)
- XXVII. **Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report**  
Paksoy N, ERDEM S., Karaca M., Ak N., Pehlivan M., KIZILDAĞ YIRGIN İ., ÖZLÜK M. Y., Ekiz F., Tural D., EKENEL M., et al.  
Journal of Oncology Pharmacy Practice, vol.28, no.1, pp.215-221, 2022 (SCI-Expanded)
- XXVIII. **FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer**  
Ay S., Atci M. M., Arıkan R., Dülger Ö., Özyükseler D. T., Paksoy N., Doğan İ., Öztosun B., Taştekin D., Öven B. B., et al.  
Journal of Chemotherapy, vol.34, no.7, pp.465-471, 2022 (SCI-Expanded)
- XXIX. **Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)**  
Erol C., Sakin A., Başoğlu T., Özden E., Çabuk D., Doğan M., Öksüzoğlu B., Yildirim H. Ç., Öner İ., Karakurt Eryılmaz M., et al.  
Turkish Journal of Medical Sciences, vol.52, no.4, pp.1022-1032, 2022 (SCI-Expanded)
- XXX. **Clinicopathological and Prognostic Features of 67 Cases with Pulmonary Sarcomatoid Carcinoma: An 18-Year Single-Centre Experience**  
Ferhatoglu F., Amirov F., Ozkan B., Kara M., Toker A., Ak N., Aydin E., Paksoy N., Yilmazbayhan D., AYDINER A.  
Oncology Research and Treatment, vol.44, no.11, pp.590-601, 2021 (SCI-Expanded)
- XXXI. **Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences**  
Tural D., ÖLMEZ Ö. F., Sümbül A. T., Artaç M., Özhan N., Akar E., Çakar B., Köstek O., EKENEL M., ERMAN M., et al.  
European Urology Focus, vol.7, no.5, pp.1061-1066, 2021 (SCI-Expanded)
- XXXII. **Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab**  
Tural D., ÖLMEZ Ö. F., Sümbül A. T., Özhan N., Çakar B., Köstek O., EKENEL M., ERMAN M., Coşkun H. Ş., Selçukbiricik F., et al.  
International Journal of Clinical Oncology, vol.26, no.8, pp.1506-1513, 2021 (SCI-Expanded)
- XXXIII. **Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?**  
Has Simsek D., Kuyumcu S., Karadogan S., Oflas M., Isik E. G., Ozkan Z. G., Paksoy N., Ekmekcioglu O., EKENEL M., Sanli Y.  
Annals of Nuclear Medicine, vol.35, no.6, pp.680-690, 2021 (SCI-Expanded)
- XXXIV. **A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions**  
Demir S., Gelincik A., Coskun R., Ozkan G., Demir N., Paksoy N., Beyaz S., Colakoglu B., Kalayoglu-Besisik S., Nalcaci M., et al.  
Annals of Allergy, Asthma and Immunology, vol.123, no.4, pp.394-397, 2019 (SCI-Expanded)
- XXXV. **Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due to proton pump inhibitors**  
Kepil Özdemir S., Gelincik A., Paksoy N., Köycü Buhari G., Öner Erkekol F., DURSUN A. B., Çelebioğlu E., KARAKAYA G., BAVBEK S.  
Allergy: European Journal of Allergy and Clinical Immunology, vol.74, no.6, pp.1187-1190, 2019 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Predictors of the acquisition of T790M mutation in EGFR mutant metastatic lung cancer patients who were treated with EGFR inhibitors**  
DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P. M., AYDINER A.  
EURASIAN JOURNAL OF PULMONOLOGY, vol.25, pp.27-32, 2023 (Peer-Reviewed Journal)
- II. **Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine**  
Doğan İ., Paksoy N., Ak N., Vatansever S., Saip P., AYDINER A.  
European Journal of Breast Health, vol.19, no.2, pp.128-133, 2023 (ESCI)
- III. **Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience**  
PAKSOY N., TRABULUS S., SEYAHİ N., ALTIPARMAK M. R.  
Namık Kemal Tıp Dergisi, vol.11, no.1, pp.27-34, 2023 (Peer-Reviewed Journal)
- IV. **Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study**  
FERHATOĞLU F., ÇAĞATAY T., OKUMUŞ N. G., AYDINER A., PAKSOY N., AK N., AYDIN E., SAİP P. M.  
Eurasian Journal of Medical Investigation, vol.7, no.2, pp.101-106, 2023 (Peer-Reviewed Journal)
- V. **Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospita**  
FERHATOĞLU F., KAPAĞAN T., PAKSOY N., AK N., MEDETALİBEYOĞLU A., ŞENKAL N., AYDIN E., VATANSEVER S.  
TURK ONKOLOJİ DERGİSİ, vol.38, no.1, pp.82-91, 2023 (ESCI)
- VI. **Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study**  
Paksoy N., Khanmammadov N., Doğan İ., Ferhatoğlu F., AHMED M. A., Karaman S., AYDINER A.  
Medicine (Spain), vol.102, no.5, 2023 (Scopus)
- VII. **Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye**  
Unal C., Selcuk N. A., Biricik F. S., Alan O., Ordu C., Selvi O., Sakin A., Sever N., Topcu Z. A., Akyildiz A., et al.  
Eurasian Journal of Medicine and Oncology, vol.7, no.3, pp.232-242, 2023 (ESCI)
- VIII. **Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib**  
DOĞAN İ., KHANMAMMADOV N., PAKSOY N., FERHATOĞLU F., AYDIN E., VATANSEVER S., SAİP P. M., AYDINER A.  
TURK ONKOLOJİ DERGİSİ, vol.37, no.4, pp.413-418, 2022 (ESCI)
- IX. **Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center**  
FERHATOĞLU F., PAKSOY N., BAŞARAN M.  
Namık Kemal Tıp Dergisi, vol.10, no.4, pp.350-356, 2022 (Peer-Reviewed Journal)
- X. **Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study**  
PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., BOZBEY H. U., KARABULUT S., TAŞTEKİN D.  
TURK ONKOLOJİ DERGİSİ, vol.37, no.4, pp.478-483, 2022 (ESCI)
- XI. **Evaluation of clinical features and risk factors related to late recurrence (>5 years) in patients with breast cancer**  
FERHATOĞLU F., AYDINER A., PAKSOY N.  
Journal of Surgery and Medicine, vol.6, no.12, pp.986-990, 2022 (Peer-Reviewed Journal)
- XII. **Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors**  
PAKSOY N., FERHATOĞLU F., DOĞAN İ., AK N., PEHLİVAN M., EKENEL M., BAŞARAN M.  
Eurasian Journal of Medical Investigation, vol.6, no.3, pp.326-331, 2022 (Peer-Reviewed Journal)
- XIII. **Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib**  
FERHATOĞLU F., KARABULUT S., PAKSOY N., TAŞTEKİN D.  
Eurasian Journal of Medical Investigation, vol.6, no.3, pp.292-298, 2022 (Peer-Reviewed Journal)
- XIV. **Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced**

### **Stage Ovarian Carcinoma**

AK N., PAKSOY N., FERHATOĞLU F., AYDIN E., DOĞAN İ., BEKTAŞ E., KARACA M., OĞUZ SOYDİNÇ H., MİNARECİ Y., SÖZEN H., et al.

TURK ONKOLOJİ DERGİSİ, vol.36, no.4, pp.438-445, 2021 (ESCI)

### **XV. Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer**

AK N., PAKSOY N., VELİDEDEOĞLU M., TURNA Z. H., DEMİRELLİ F. H.

Journal of oncological sciences, vol.7, no.2, pp.42-49, 2021 (Scopus)

## **Books & Book Chapters**

- I. **Over Kanseri Tedavisinde İmmünoterapinin Yeri**  
DEMİRCİ N. S., PAKSOY N.  
in: HEREDİTER JİNEKOLOJİK KANSERLER VE MOLEKÜLER PATOLOJİNİN PROGNOZ VE TEDAVİDEKİ ROLÜ, ÜNAL Orhan, Editor, Türkiye Klinikleri Tıp Bilimleri Dergisi, Ankara, pp.90-93, 2022
- II. **Merkel Hücreli Karsinom**  
PAKSOY N., KHANMAMMADOV N.  
in: NADİR TÜMÖRLER, SEDEF Ali Murat, Editor, Akademisyen Kitapevi, Ankara, pp.421-427, 2022
- III. **Gastroözofageal Bileşke Kanserin Tedavisinde neoadjuvan ve adjuvan Tedaviler**  
DEMİRCİ N. S., PAKSOY N.  
in: GASTROÖZOFAGEAL BİLEŞKE KANSERLERİ, ÖZÇELİK Mehmet Faik, GÖKSOY Ertuğrul, Editor, Türkiye Klinikleri Tıp Bilimleri Dergisi, Ankara, pp.63-69, 2022
- IV. **Paraneoplastik Osteomalazi**  
PAKSOY N., KHANMAMMADOV N.  
in: PARANEOPLASTİK SENDROMLAR, SEDEF Ali Murat, Editor, Akademisyen Kitapevi, Ankara, pp.163-171, 2022
- V. **Onkoloji Hastalarında Konstipasyona Yaklaşım**  
PAKSOY N.  
in: ONKOLOJİDE DESTEK TEDAVİLER VE SEMPTOM YÖNETİMİ, AKAGÜNDÜZ Baran, Editor, Akademisyen Kitapevi, Ankara, pp.179-189, 2021
- VI. **Anaplastik Tiroid Kanseri**  
PAKSOY N.  
in: TİROİD BEZİ VE HASTALIKLARINA MULTİDİSİPLİNER YAKLAŞIM, AKBAŞ Emin Murat, Editor, Akademisyen Kitapevi, Ankara, pp.331-336, 2021
- VII. **İmmünoterapilere Bağlı Gelişen Akut Yan Etkilerin Yönetimi.**  
PAKSOY N.  
in: Onkolojik Aciller, SEDEF Ali Murat, Editor, Akademisyen Kitapevi, Ankara, pp.235-255, 2021
- VIII. **Kanser**  
SAKA B., PAKSOY N., YENEREL M. N.  
in: Geriatri Yaşlı Sağlığı ve Hastalıkları, Ülger Zekeriya , Erdinçler Ülev Deniz, Karan Mehmet Akif, Editor, HİPOKRAT, Ankara, pp.349-380, 2021

## **Refereed Congress / Symposium Publications in Proceedings**

- I. **Metastasectomy in oligometastatic RCC brings a survival benefit in immunotherapy era: Results from the REMARCC-IO Registry**  
Primiceri G., Marchioni M., Campi R., Tafuri A., Autorino R., Minervini A., Kriegmair M., Rebez G., Erdem S., Paksoy N., et al.  
vol.83
- II. **Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of**

**metastatic colorectal cancer: A Turkish oncology group study**

Tasçi E, Oyan B, Sonmez O, Mutlu A, Atci M, Oner I, Cinkir H, Eryilmaz M, Balçık O, Paksoy N, et al.  
vol.40

III. **Cytoreductive nephrectomy in patients receiving TKI therapy versus immune checkpoint inhibitor therapy: Comparative outcome analysis of the REMARCC registry**

Meagher M, Minervini A, Mir M, Rebez G, Autorino R, Campi R, Kriegmair M, Linares E, Hevia V, Musquera M, et al.  
vol.79

IV. **Predictors of complications after cytoreductive nephrectomy in the immunotherapy era: Results from a multicenter international study**

Marchioni M, Rebez G, Campi R, Minervini A, Kriegmair M, Linares E, Hevia V, Veccia A, Carbonara U, Musquera M, et al.  
vol.79

V. **Is presence of vena caval thrombosis in primary tumor associated with worsened outcomes in metastatic renal cell carcinoma: Analysis of the REMARCC registry**

Meagher M, Mir M, Rebez G, Autorino R, Campi R, Minervini A, Kriegmair M, Linares E, Hevia V, Musquera M, et al.  
vol.79

## **Metrics**

Publication: 63

Citation (WoS): 81

Citation (Scopus): 81

H-Index (WoS): 5

H-Index (Scopus): 5